Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech Inc. has announced the acceptance of data from its ongoing Phase 2 clinical study of Ampligen® (rintatolimod) for treating cisplatin-resistant advanced recurrent ovarian cancer. The data will be presented at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. This single-arm trial, conducted by the University of Pittsburgh Medical Center, shows promising results with a clinical benefit rate of 61.6% among 13 evaluable patients. The study aims to confirm these findings while enhancing our understanding of the tumor microenvironment.
AIM ImmunoTech Inc. (NYSE: AIM) announced that its drug candidate, Ampligen®, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022. Oncology experts from Roswell Park Comprehensive Cancer Center will share findings from two ongoing clinical studies involving Ampligen®. The first study evaluates a chemokine-modulatory regimen in colorectal cancer patients, while the second focuses on enhancing cytotoxic T-lymphocyte influx in metastatic triple-negative breast cancer. Both presentations are scheduled for April 11, 2022, in New Orleans, Louisiana.
AIM ImmunoTech announced promising data regarding Ampligen® (rintatolimod) as a treatment for advanced pancreatic cancer in an Early Access Program at Erasmus Medical Center. The treatment showed a median overall survival of 19 months versus historical controls of 7.5 and 12.5 months. A Phase 2 study is set to begin in 2022, aiming to evaluate Ampligen's efficacy post-FOLFIRINOX. The study's positive endpoints include improved survival rates and increased B-cell counts, providing hope for patients with limited treatment options.
AIM ImmunoTech Inc. has announced the sale of its New Brunswick, New Jersey facility for $3.9 million. This strategic move aims to reduce operational expenses by over $1 million annually, allowing the company to focus on advancing its oncology and long-COVID clinical programs. CEO Thomas Equels emphasized the importance of this transaction in streamlining their processes toward FDA and EMA drug approvals. AIM will retain access to the facility for specific activities and plans to lease additional space for product development.
AIM ImmunoTech Inc. has appointed Robert Dickey IV as its new Chief Financial Officer, effective April 4, 2022. Dickey, a financial leader with over 25 years of experience in life sciences and medical devices, replaces Ellen Lintal, who will transition to a consulting role. AIM is poised for significant growth with six ongoing oncology clinical trials and multiple data readouts expected within the next year. The company believes Dickey's extensive background in capital markets and business development will bolster its strategic initiatives.
AIM ImmunoTech has announced participation in a webinar on January 27, 2022, from 2:00 PM to 3:00 PM ET, focusing on the clinical plans for the investigational drug Ampligen in treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.
The session will feature key executives discussing the drug's development, which has shown promise in improving cognitive function among patients. Attendees can register for the event through the provided link.
AIM ImmunoTech announced positive results from a Phase 1/2 clinical study on its intraperitoneal chemo-immunotherapy for advanced recurrent ovarian cancer. The study, demonstrating a well-tolerated safety profile, involved 12 patients and highlighted a 55.6% overall response rate and a median overall survival of 30 months. The promising results support the advancement to a Phase 2 trial, evaluating the immunologic and clinical efficacy of a tumor-loaded αDC1 vaccine combined with cisplatin and chemokine modulation. This development is expected to provide hope for patients and create shareholder value.
AIM ImmunoTech Inc. (NYSE: American AIM) announced a live video webcast presentation on January 26, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO Thomas K. Equels will present the company’s advancements in therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. The event will feature a corporate presentation followed by an interactive Q&A session. Interested parties may submit questions live or in advance. The presentation will be accessible via the company's website, with a replay available for one year.
AIM ImmunoTech announced that safety data for its drug Ampligen was presented at the Eighth European Scientific Working Group on Influenza conference held virtually from December 4-7, 2021. The Centre for Human Drug Research shared interim results from a Phase 1 clinical study, which involved 40 healthy subjects. The study showed no severe adverse events at various dosages of Ampligen. AIM expects to receive the complete study report in January 2022. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) announces CEO Thomas Equels' participation in two significant investor conferences. He will join the 'COVID-19: What’s Next in Prevention, Treatment & Diagnostics' panel at the BioFlorida Conference on December 9, 2021, at 1:45 PM EST, and also partake in the CEO Forum later that day. Additionally, Equels is scheduled to speak at the Benzinga All Access event on December 16, 2021, at 11:20 AM EST. These engagements highlight AIM's commitment to addressing urgent health issues, including COVID-19 and cancer treatments.
FAQ
What is the current stock price of AIM ImmunoTech (AIM)?
What is the market cap of AIM ImmunoTech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
